Moleculin Biotech Stock Price, News & Analysis (NASDAQ:MBRX)

$1.63 0.00 (0.00 %)
(As of 11/22/2017 07:47 AM ET)
Previous Close$1.63
Today's Range$1.62 - $1.69
52-Week Range$0.71 - $3.75
Volume172,200 shs
Average Volume1.31 million shs
Market Capitalization$34.45 million
P/E RatioN/A
Dividend YieldN/A
Beta-1.67

About Moleculin Biotech (NASDAQ:MBRX)

Moleculin Biotech logoMoleculin Biotech, Inc. is a preclinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). Annamycin is a Phase II clinical-stage anthracycline and liposome formulated anthracycline that has been designed to eliminate cardiotoxicity and avoid the multidrug resistance mechanisms. It has over two other drug development projects in progress, one involving a portfolio of small molecules, which it refers to as the WP1066 Portfolio, focused on the modulation of key oncogenic transcription factors involved in the progression of cancer, and the WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer in general, and glioblastoma. As of April 3, 2017, it had not generated any revenue from its operations.


Industry, Sector and Symbol:
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: NASDAQ:MBRX
  • CUSIP: N/A
  • Web: www.moleculin.com
Debt:
  • Current Ratio: 5.17%
  • Quick Ratio: 5.17%
Sales & Book Value:
  • Annual Sales: N/A
  • Price / Sales: N/A
  • Book Value: $0.88 per share
  • Price / Book: 1.85
Profitability:
  • Trailing EPS: ($0.47)
  • Net Income: $-3,920,000.00
  • Return on Equity: -40.84%
  • Return on Assets: -35.87%
Misc:
  • Employees: 6
  • Outstanding Shares: 21,140,000
 

Frequently Asked Questions for Moleculin Biotech (NASDAQ:MBRX)

What is Moleculin Biotech's stock symbol?

Moleculin Biotech trades on the NASDAQ under the ticker symbol "MBRX."

How were Moleculin Biotech's earnings last quarter?

Moleculin Biotech, Inc. (NASDAQ:MBRX) announced its quarterly earnings data on Tuesday, November, 14th. The company reported ($0.14) earnings per share for the quarter. View Moleculin Biotech's Earnings History.

Who are some of Moleculin Biotech's key competitors?

How do I buy Moleculin Biotech stock?

Shares of Moleculin Biotech can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Moleculin Biotech's stock price today?

One share of Moleculin Biotech stock can currently be purchased for approximately $1.63.

How big of a company is Moleculin Biotech?

Moleculin Biotech has a market capitalization of $34.45 million. The company earns $-3,920,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis. Moleculin Biotech employs 6 workers across the globe.

How can I contact Moleculin Biotech?

Moleculin Biotech's mailing address is 2575 WEST BELLFORT SUITE 333, HOUSTON TX, 77054. The company can be reached via phone at 713-300-5160.


MarketBeat Community Rating for Moleculin Biotech (NASDAQ MBRX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  44 (Vote Outperform)
Underperform Votes:  32 (Vote Underperform)
Total Votes:  76
MarketBeat's community ratings are surveys of what our community members think about Moleculin Biotech and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Moleculin Biotech (NASDAQ:MBRX)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Analysts' Consensus Price Target: N/A

Consensus Price Target History for Moleculin Biotech (NASDAQ:MBRX)

Price Target History for Moleculin Biotech (NASDAQ:MBRX)

Analysts' Ratings History for Moleculin Biotech (NASDAQ:MBRX)

Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History and Estimates Chart for Moleculin Biotech (NASDAQ:MBRX)

Earnings by Quarter for Moleculin Biotech (NASDAQ:MBRX)

Earnings History by Quarter for Moleculin Biotech (NASDAQ MBRX)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2017Q3 2017($0.14)ViewN/AView Earnings Details
8/14/2017Q2 2017($0.19)ViewN/AView Earnings Details
5/15/2017Q1 2017($0.02)ViewN/AView Earnings Details
11/21/2016Q316($0.12)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Moleculin Biotech (NASDAQ:MBRX)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Moleculin Biotech (NASDAQ:MBRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Moleculin Biotech (NASDAQ MBRX)

Insider Ownership Percentage: 20.80%
Institutional Ownership Percentage: 4.92%
Insider Trades by Quarter for Moleculin Biotech (NASDAQ:MBRX)

Insider Trades by Quarter for Moleculin Biotech (NASDAQ MBRX)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/16/2017Waldemar PriebeMajor ShareholderSell100,000$1.70$170,000.00View SEC Filing  
5/11/2017Walter V. KlempCEOBuy12,000$0.81$9,720.00View SEC Filing  
5/5/2017Jacqueline NorthcutDirectorBuy1,000$0.82$820.00View SEC Filing  
4/28/2017Robert E GeorgeDirectorBuy1,000$0.94$940.00View SEC Filing  
4/25/2017Jonathan P FosterInsiderBuy10,000$0.86$8,600.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Moleculin Biotech (NASDAQ MBRX)

Source:
DateHeadline
Moleculin to Present at the 10th Annual LD Micro Main Event on December 5, 2017 at 11:30 a.m. PTMoleculin to Present at the 10th Annual LD Micro Main Event on December 5, 2017 at 11:30 a.m. PT
finance.yahoo.com - November 22 at 2:53 AM
Moleculin Biotech, Inc. (MBRX) Announces Quarterly  Earnings ResultsMoleculin Biotech, Inc. (MBRX) Announces Quarterly Earnings Results
www.americanbankingnews.com - November 15 at 1:13 PM
Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2017Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2017
finance.yahoo.com - November 15 at 6:12 AM
Moleculin Biotech, Inc. (MBRX) Set to Announce Earnings on MondayMoleculin Biotech, Inc. (MBRX) Set to Announce Earnings on Monday
www.americanbankingnews.com - November 13 at 2:08 AM
Moleculin Appoints Dr. Sandra Silberman as Chief Medical Officer -- New ProductsMoleculin Appoints Dr. Sandra Silberman as Chief Medical Officer -- New Products
finance.yahoo.com - November 8 at 4:56 PM
Moleculin Announces MD Anderson has Filed an IND with the FDA on its Drug WP1066 for the Treatment of Brain TumorsMoleculin Announces MD Anderson has Filed an IND with the FDA on its Drug WP1066 for the Treatment of Brain Tumors
finance.yahoo.com - November 2 at 6:14 AM
Moleculin Requests Authorization from the Polish Government to Advance AnnamycinMoleculin Requests Authorization from the Polish Government to Advance Annamycin
finance.yahoo.com - October 25 at 7:01 AM
Moleculin Requests Authorization from the Polish Government to Advance AnnamycinMoleculin Requests Authorization from the Polish Government to Advance Annamycin
finance.yahoo.com - October 25 at 7:01 AM
Moleculin Announces 14 Qualified Clinical Sites Requesting Participation in Annamycin TrialMoleculin Announces 14 Qualified Clinical Sites Requesting Participation in Annamycin Trial
finance.yahoo.com - October 19 at 6:08 AM
Moleculin Announces Strategic Collaboration to Develop Immune Stimulation DrugMoleculin Announces Strategic Collaboration to Develop Immune Stimulation Drug
finance.yahoo.com - October 11 at 3:19 PM
Corporate News Blog - Moleculin Biotech Signs Agreement with the First Hospital to Conduct Clinical Trials for AnnamycinCorporate News Blog - Moleculin Biotech Signs Agreement with the First Hospital to Conduct Clinical Trials for Annamycin
finance.yahoo.com - October 6 at 10:16 AM
Moleculin Signs Agreement with First Hospital for Annamycin TrialsMoleculin Signs Agreement with First Hospital for Annamycin Trials
finance.yahoo.com - October 4 at 6:47 AM
Moleculin Announces FDA Approval of Annamycin INDMoleculin Announces FDA Approval of Annamycin IND
finance.yahoo.com - October 2 at 12:02 PM
Todays Research Reports on Stocks to Watch: Axovant and MoleculinToday's Research Reports on Stocks to Watch: Axovant and Moleculin
finance.yahoo.com - October 2 at 12:02 PM
Corporate News Blog - FDA Grants Approval to Moleculin Biotech for Clinical Trials of Annamycin in the Treatment of AMLCorporate News Blog - FDA Grants Approval to Moleculin Biotech for Clinical Trials of Annamycin in the Treatment of AML
finance.yahoo.com - October 2 at 12:02 PM
Moleculin Engages CRO to Begin Clinical Trials of WP1220 for the Treatment of Cutaneous T-Cell LymphomaMoleculin Engages CRO to Begin Clinical Trials of WP1220 for the Treatment of Cutaneous T-Cell Lymphoma
finance.yahoo.com - September 14 at 7:29 AM
Moleculin to Collaborate on Combining its WP1122 Brain Cancer Drug Candidate with Roches Drug AvastinMoleculin to Collaborate on Combining its WP1122 Brain Cancer Drug Candidate with Roche's Drug Avastin
finance.yahoo.com - September 7 at 1:01 AM
Moleculin Announces Participation at the 19th Annual Rodman & Renshaw Global Investment ConferenceMoleculin Announces Participation at the 19th Annual Rodman & Renshaw Global Investment Conference
finance.yahoo.com - September 1 at 3:32 AM
Moleculin Announces Filing with FDA of IND for its Leukemia Drug AnnamycinMoleculin Announces Filing with FDA of IND for its Leukemia Drug Annamycin
finance.yahoo.com - August 30 at 6:23 AM
Moleculin to meet with EMA on trial design for AML candidate AnnamycinMoleculin to meet with EMA on trial design for AML candidate Annamycin
seekingalpha.com - August 24 at 9:01 AM
Corporate News Blog - Moleculin Biotech to Meet European Medicines Agency; Discussion on Clinical Trial Authorization for the Treatment of Acute Myeloid LeukemiaCorporate News Blog - Moleculin Biotech to Meet European Medicines Agency; Discussion on Clinical Trial Authorization for the Treatment of Acute Myeloid Leukemia
finance.yahoo.com - August 24 at 9:01 AM
Moleculin Announces Meeting with European Medicines AgencyMoleculin Announces Meeting with European Medicines Agency
finance.yahoo.com - August 22 at 8:48 PM
Moleculin Biotech, Inc. (MBRX) Major Shareholder Waldemar Priebe Sells 100,000 SharesMoleculin Biotech, Inc. (MBRX) Major Shareholder Waldemar Priebe Sells 100,000 Shares
www.americanbankingnews.com - August 18 at 8:32 PM
Biotech Sector Rises on Accelerated Anti-cancer Drug Candidate Developments and Clinical Trial ProgressBiotech Sector Rises on Accelerated Anti-cancer Drug Candidate Developments and Clinical Trial Progress
www.prnewswire.com - August 18 at 8:18 PM
Moleculin Biotech (MBRX) Buys Active Drug Compound for Treatment of Brain CancerMoleculin Biotech (MBRX) Buys Active Drug Compound for Treatment of Brain Cancer
www.streetinsider.com - August 17 at 2:06 AM
Moleculin Acquires Active Drug Compound for the Treatment of Brain CancerMoleculin Acquires Active Drug Compound for the Treatment of Brain Cancer
finance.yahoo.com - August 17 at 2:06 AM
Moleculin Biotech, Inc. (MBRX) Issues  Earnings ResultsMoleculin Biotech, Inc. (MBRX) Issues Earnings Results
www.americanbankingnews.com - August 15 at 12:46 PM
Moleculin Biotech, Inc. Reports Financial Results for the Second Quarter Ended June 30, 2017Moleculin Biotech, Inc. Reports Financial Results for the Second Quarter Ended June 30, 2017
finance.yahoo.com - August 15 at 1:19 AM
Moleculin Updates Annamycin Progress, Analyst Coverage, Price Target and Full Pipeline ReviewMoleculin Updates Annamycin Progress, Analyst Coverage, Price Target and Full Pipeline Review
finance.yahoo.com - August 15 at 1:19 AM
Moleculin Biotech, Inc. (NASDAQ:MBRX) Sees Significant Increase in Short InterestMoleculin Biotech, Inc. (NASDAQ:MBRX) Sees Significant Increase in Short Interest
www.americanbankingnews.com - August 13 at 1:46 AM
Moleculin Comments on Recent FDA Drug Approvals for Acute Myeloid LeukemiaMoleculin Comments on Recent FDA Drug Approvals for Acute Myeloid Leukemia
finance.yahoo.com - August 10 at 4:40 AM
Moleculin Begins Clinical Testing Site Development Efforts in Poland; Selects Bioscience SA as Polish CROMoleculin Begins Clinical Testing Site Development Efforts in Poland; Selects Bioscience SA as Polish CRO
finance.yahoo.com - August 4 at 1:18 AM
Moleculin Biotech, Inc. (MBRX) Short Interest UpdateMoleculin Biotech, Inc. (MBRX) Short Interest Update
www.americanbankingnews.com - July 28 at 1:46 AM
Moleculins New Drug for the Treatment of Glioblastoma Nears Clinical Trials at MD Anderson Cancer CenterMoleculin's New Drug for the Treatment of Glioblastoma Nears Clinical Trials at MD Anderson Cancer Center
finance.yahoo.com - July 25 at 11:32 PM
Featured Company News - Moleculin Biotech Signs License Agreement with MD Anderson Cancer Center for its Lead Product Candidate, AnnamycinFeatured Company News - Moleculin Biotech Signs License Agreement with MD Anderson Cancer Center for its Lead Product Candidate, Annamycin
finance.yahoo.com - July 21 at 2:03 AM
Moleculin Biotech (MBRX) Reports Agreement with MD Anderson Cancer Center for Leukemia Drug, AnnamycinMoleculin Biotech (MBRX) Reports Agreement with MD Anderson Cancer Center for Leukemia Drug, Annamycin
www.streetinsider.com - July 18 at 11:09 PM
Moleculin Biotech, Inc. (NASDAQ:MBRX) Short Interest Up 250.7% in JuneMoleculin Biotech, Inc. (NASDAQ:MBRX) Short Interest Up 250.7% in June
www.americanbankingnews.com - July 15 at 7:22 AM
Moleculin Regains Compliance with NASDAQ Listing RequirementsMoleculin Regains Compliance with NASDAQ Listing Requirements
finance.yahoo.com - July 13 at 6:38 AM
Moleculin Appoints Lead European Principal Investigator for Planned Annamycin Clinical TrialMoleculin Appoints Lead European Principal Investigator for Planned Annamycin Clinical Trial
finance.yahoo.com - July 7 at 7:17 AM
Gainers & Losers Of June 26: AVEO, MBRX, SELB, NEOT, SGEN...Gainers & Losers Of June 26: AVEO, MBRX, SELB, NEOT, SGEN...
www.finanznachrichten.de - June 27 at 2:24 AM
Moleculin Biotech (MBRX) Reports Significant Discovery with Potential to Treat Pancreatic CancerMoleculin Biotech (MBRX) Reports Significant Discovery with Potential to Treat Pancreatic Cancer
www.streetinsider.com - June 22 at 8:50 AM
U.S. Futures Narrowly Mixed as Wall Street Shifts Focus to OilU.S. Futures Narrowly Mixed as Wall Street Shifts Focus to Oil
www.nasdaq.com - June 22 at 8:50 AM
Commercial Metals (CMC) Tops Q2 EPS by 16cCommercial Metals (CMC) Tops Q2 EPS by 16c
www.streetinsider.com - March 24 at 9:12 AM
Moleculin Receives Orphan Drug Designation for Annamycin for the Treatment of Acute Myeloid LeukemiaMoleculin Receives Orphan Drug Designation for Annamycin for the Treatment of Acute Myeloid Leukemia
us.rd.yahoo.com - March 22 at 6:35 PM
Moleculin Leukemia Drug Gets Orphan Drug StatusMoleculin Leukemia Drug Gets Orphan Drug Status
us.rd.yahoo.com - March 22 at 6:35 PM
MOLECULIN BIOTECH, INC. Files SEC form 8-K, Changes in Registrants Certifying Accountant, Financial Statements and EMOLECULIN BIOTECH, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and E
biz.yahoo.com - February 23 at 6:27 PM
Moleculin Announces Pricing of $5 Million Underwritten Public OfferingMoleculin Announces Pricing of $5 Million Underwritten Public Offering
www.marketwatch.com - February 9 at 7:25 PM
MOLECULIN BIOTECH, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial StateMOLECULIN BIOTECH, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial State
biz.yahoo.com - February 9 at 7:25 PM
Moleculin Biotech Inc. (MBRX) Is Accelerating To The UpsideMoleculin Biotech Inc. (MBRX) Is Accelerating To The Upside
www.rttnews.com - December 27 at 6:23 PM
7:31 am Moleculin Biotech presents data for its WP1122 portfolio at the 28th EORTC-NCI-AACR Symposium, including data demonstrating increased survival of animals with human brain tumors treated with WP11227:31 am Moleculin Biotech presents data for its WP1122 portfolio at the 28th EORTC-NCI-AACR Symposium, including data demonstrating increased survival of animals with human brain tumors treated with WP1122
us.rd.yahoo.com - December 13 at 6:53 PM

Social Media

Financials

Chart

Moleculin Biotech (NASDAQ MBRX) Chart for Wednesday, November, 22, 2017
Loading chart…

This page was last updated on 11/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.